ArticleBioresources and bioprocessing2026
Exploration of the mechanism of Xinjiang Rosa laxa Retz.Fruit extract on IgA nephropathy by bioinformatics and machine learning methods.
Article in Bioresources and bioprocessing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study aimed to elucidate the core therapeutic targets and mechanisms of action of rosehip extract (FRLE) in IgA nephropathy (IgAN) by integrating bioinformatics, machine learning, and computational simulation techniques to simultaneously analyze the therapeutic effects of FRLE on IgAN. Through screening differentially expressed genes in IgAN patients and identifying potential target proteins of the core components of FRLE, 118 overlapping targets were ultimately determined as the gene set involved in the synergistic interaction between the two. Through triple machine learning validation, FGR and LDHB were identified as core target proteins, with Ellagic acid, Rutin, and Hyperoside as the core active components. In IgAN patients, LDHB was significantly downregulated, while FGR was significantly upregulated. Both demonstrated excellent diagnostic efficacy and were closely associated with the renal immune microenvironment. Molecular docking and molecular dynamics simulations confirmed that the core components could stably bind to FGR and LDHB. In summary, FRLE targets and modulates FGR and LDHB through its core components, intervening in inflammatory pathways and immune microenvironment imbalance, thereby providing a theoretical basis for subsequent experiments and clinical translation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.